Cyteir Therapeutics is a biotech firm specialising in oncology medication. Their leading product, CYT-0851, is a small molecule drug presently in Phase I/II of clinical trials for both monotherapy and combination therapy in hematologic malignancies and solid tumors. The company's headquarters are in Lexington, Massachusetts, and they were established in 2012.